Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 3 days ago

Silence Therapeutics plc: Invus Global Management, LLC amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 12 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Invus Global Management, LLC amended its Schedule 13G stake filing for Silence Therapeutics plc, disclosing the change to the SEC under accession number 0002005369-26-000060. The filing updates Invus's previously reported beneficial ownership position in the London-listed biotech. The specific revised share count and percentage were not detailed in the headline release. Investors should watch for the full filing text to confirm whether the change reflects an increase or reduction in Invus's holding.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Silence Therapeutics plc, Invus Global Management, LLC